Innovent Biologics, Inc. (HKG:1801)
102.90
+2.95 (2.95%)
Jul 30, 2025, 9:45 AM HKT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
17.04
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
170.86B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Akeso | 2.26B |
WuXi Biologics | 19.87B |
Sino Biopharmaceutical | 30.72B |
CSPC Pharmaceutical Group | 28.99B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Innovent Biologics News
- 13 days ago - Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - PRNewsWire
- 14 days ago - ‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution - South China Morning Post
- 4 weeks ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 4 weeks ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 4 weeks ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 5 weeks ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 5 weeks ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha
- 5 weeks ago - Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions - PRNewsWire